Low Serum 25(OH)D Levels in Parkinson’s Disease; a Non Specific Marker of Neurodegeneration?

Olivia Enrica1, Cerroni Rocco1, Conti Marco1, Pierantozzi Mariangela1, Lugliero Claudio2 and Stefani Alessandro*1

1Movement Disorders Centre, Department of Systems Medicine, University of Rome “Tor Vergata”, Italy
2Sleep Disorders Centre, Department of Systems Medicine, University of Rome “Tor Vergata”, Italy

Abstract

Objective: Several investigations have recently inferred that a low serum vitamin D concentration may contribute to cognitive impairment in the elderly. Here, we assessed whether in a cohort of Parkinson’s disease (PD) patients attributable to any disease stage a deficit in serum 25-hydroxyvitamin D (25(OH)D) levels occurred as previously proposed and, more importantly, if it is correlated with cognitive impairment or disease duration.

Methods: Our PD group (n=54) was compared to an age-matched control group (n=30), but also to patients affected by Alzheimer’s disease (AD) (n=17) and motor neuron disease (amyotrophic lateral sclerosis - ALS) (n=19).

Results: Serum 25(OH)D levels > 30 ng/ml was found in 37% of PD patients (versus 76% in controls); in 34 out of 54 PD patients low 25(OH)D levels occurred (28.73 ± 20.22 ng/ml vs 44.52 ± 18.48 ng/ml in control group); however, no correlation with mini mental state examination (MMSE) or disease progression emerged in PD patients. AD cohort was characterized by a significantly lower vitamin D concentration (half manifesting severe deficiency below 10 ng/ml, in contrast with 18% amongst PD). To note, also in ALS, pathological low levels of vitamin D, comparable to PD, was found.

Conclusion: Our findings highlight that vitamin D insufficiency or deficiency is shared by multiple neurodegenerative diseases, albeit a-specifically. In PD, 25(OH)D levels do not correlate with cognitive performance. On one hand, these data confirm the opportunity to restore vitamin D levels in a variety of neurological disorders; on the other, they suggest that, in PD, at contrast with AD, vitamin D insufficiency should not play a relevant role in influencing disease severity or unmasking an associated dementia.

Keywords: Parkinson’s disease; Vit D levels; Alzheimer’s disease; Motor neuron disease; Cognitive performance

Introduction

In recent years, several studies have been focused on the extraskeletal effects of vitamin D, which is intended as a steroid hormone, exerting cardiovascular, immunomodulatory, anti-tumoral effects in human body by regulating the expression of hundreds of genes through both genetic and epigenetic mechanisms [1-4]. Furthermore, growing evidence highlight the possible role of vitamin D in neuroprotection through neuronal calcium regulation, antioxidative pathway, immunomodulation and detoxification [5,6]. On the other side, vitamin D deficiency may correlate with neuroinflammatory-autoimmune cascade, cerebrovascular lesions and, most recently, with neurodegenerative diseases [7-11].

In the context of a growing interest in biomarkers of neurodegenerative diseases [12,13] the correlation between vitamin D deficiency and neurodegeneration is becoming the real hot topic. Scientific literature in the last years emphasized the correlation between Alzheimer Disease (AD) and low levels of vitamin D. Recent meta-analyses confirmed that low serum vitamin D concentrations are associated with the impairment of specific cognitive domains, such as memory and executive functions [14,15]. Van der Schaft and colleagues conducted a systematic review including a cross-sectional and 6 prospective studies showing that 72% of the studies significantly exhibited either worse outcome on one or more cognitive function tests or a higher frequency of dementia if lower 25-hydroxyvitamin D (25(OH)D) levels or insufficient vitamin D intake occurred [16]. Llewellyn and coauthors showed an inverse relationship between serum 25(OH)D levels and cognitive impairment [17]. A large, prospective, population-based study conducted to examine the relationship of dementia and AD with vitamin D concentration confirmed that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and AD [18]. These data candidate vitamin D deficiency as a predictor factor for dementia.

The relationship between vitamin D and Parkinson Disease (PD) is less unequivocal. Previous studies have shown a strong correlation between motor dysfunction and vitamin D shortage (outdoor activity and total vitamin D intake are inversely associated with PD [19] but no conclusive evidence links cognitive dysfunctions and low vitamin D levels. A cross-sectional and longitudinal case-control study of 388 patients (mean Hoehn and Yahr stage of 2.1 ± 0.6) and 283 control subjects showed an increased frequency of vitamin D deficiency in PD patients compared to controls and a correlation of low 25(OH)D levels with higher total Unified Parkinson’s Disease rating Scale (UPDRS) scores at baseline and during follow up [20]. By the psycho-cognitive side, a longitudinal study suggested that higher plasma vitamin D level is associated with better cognition and better mood in PD patients without dementia [21].

*Corresponding author: Alessandro Stefani, Department of Systems Medicine, University of Rome, “Tor Vergata”, Rome, Italy. Tel: +39-6-20903115; Fax: 39620903118; E-mail: stefani@uniroma2.it

Received October 19, 2015; Accepted December 07, 2015; Published December 14, 2015


Copyright: © 2015 Enrica O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The aim of our study was to verify if vitamin D deficiency is a peculiar element of PD, as already assessed in AD, or if it is a more general biomarker of senescence and neurodegenerative processes, as suggested by studies focused over others degenerative diseases like myotonic dystrophy type I [22] or multiple sclerosis (MS) [23,24]. To our purpose we compared a population of PD patients not only with healthy controls, but also with AD patients and amyotrophic lateral sclerosis (ALS) patients. In PD patients, we also investigated whether an inverse relationship between serum 25(OH)D levels and mini mental state examination (MMSE) took place, as already demonstrated in AD patients.

Materials and Methods

One hundred twenty patients were included in the study: 54 with PD, 30 age-matched normal subjects and for comparative purposes a group of 17 patients with AD and 19 patients with ALS. Hepatic dysfunction, renal insufficiency and vitamin D supplementation were considered exclusion criteria. All subjects provided informed consent and underwent evaluation including a general neurological examination, laboratory tests and neuropsychological assessments MMSE. Serum 25(OH)D was measured by radioimmunoassay in all participants. All samples were collected during the same season. In PD group the disease severity was evaluated using the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) and Hoehn and Yahr stage (H&Y). Vitamin D levels > 30 ng/ml were considered as normal, levels of 20–30 ng/ml represented insufficiency, whereas levels below 20 and 10 ng/ml represented respectively deficiency and severe deficiency [25,26].

Statistics

Results are expressed as mean ± SD or as number (percentages). Significant differences in demographic and vitamin D levels among groups were separately analyzed by performing Kruskal–Wallis test, then the Mann–Whitney U test was performed to compare significant Kruskal–Wallis results. Correlation coefficient (Spearman) was calculated to assess the relationship between variables. Statistical significance was defined as p values lower than 0.05.

Results

No significant differences in age and distribution of male/female ratio were observed comparing the studied groups (demographic data and serum 25(OH)D level are shown in (Table 1). The Kruskal-Wallis test showed significant differences in vitamin D levels among groups (p < 0.001). The PD group showed significant lower serum vitamin D levels compared to the controls (p < 0.001), with a mean value of 28.73 ± 20.22 ng/ml (vs 44.52 ± 18.48 ng/ml). Moreover, 34 PD patients (nearly 60%) showed levels of vitamin D below 30 ng/ml, in particular 9 patients out of the 34 exhibited levels of vitamin D between 20 and 30 ng/ml (insufficiency), 15 had levels between 10 and 20 ng/ml (deficiency), whereas the remaining 10 showed vitamin D lower than 10 ng/ml (severe deficiency). Figures 1A and 1B illustrate cake diagrams of the vitamin D levels in the two groups. No difference in vitamin D levels was observed between male and female either in PD or control subjects; no correlation between age and vitamin D levels was observed in PD or control subjects (R=0,18 p=0,19 in PD; R=-0,07 p=0,70 in controls). Furthermore, in both groups vitamin D levels were not correlated with MMSE score (R=0,17 p=0,20 in PD; R=0,19 p=0,29 in control group) (Scatterplots are shown in Figure 2). In addition, there were no significant difference in vitamin D levels dividing PD patients

![Figure 1](image-url)
for age (below and above 70 years), gender, MMSE score and disease severity as measured by Hoehn & Yahr (H&Y) stages: no significant difference in levels of vitamin D were found comparing PD patients with H&Y < 2 (n=14) and H&Y ≥2 (n=40) and comparing patients with MMSE ≤ 20/30 (n=5) and MMSE >20/30 (n=49) (Table 2).

For comparative purposes a group of 17 patients with AD was also examined. In AD patients vitamin D levels showed a significant reduction (p < 0.001) compared to controls. Nearly half of the AD patients (47%) had levels of vitamin D lower than10 ng/ml (severe deficiency) (Figure 1C). In fact, as expected, difference in vitamin D levels between AD and PD group was significant (p < 0.001). Also in AD group vitamin D levels did not correlated with age (R=−0.19 p=0.47). The small cohort hampered to find a strong correlation with MMSE (yet, R=0.48 p= 0.052) (Scatterplots are shown in Figure 3). Finally, we took advantage of a coeval population of patients afflicted by ALS. Also this group showed vitamin D levels significantly lower
than controls (p < 0.05); however, about half of the ALS patients (53%) had normal levels of vitamin D (>30 ng/ml) and only 5% (one patient) showed vitamin D lower than 10 ng/ml (severe deficiency) (Figure 1D). To note, no significant difference was found comparing ALS with PD group (p=0.25).

**Discussion**

Our study emphasized that most PD patients manifested a low serum 25(OH)D levels. However, this finding was tempered by two evidence: first, the absence of correlation with MMSE or disease staging; second, also patients afflicted by motor neuron disease exhibited similar deficiency.

On the other hand, our study highlights once more that AD patients manifest a clearcut vitamin D deficiency; such an impairment is significantly more pronounced than other populations affected by different neurodegenerative disorders. 47 % of the AD cohort showed indeed vitamin D levels <10 ng/ml, indicative of severe deficiency; whilst both PD and ALS, albeit characterized by pathological serum levels, in the majority of cases showed levels > 20 ng/ml. In PD, for instance, only 18% manifest severe deficiency and in ALS group only 5%. On the other hand, the significant low level in PD compared to controls suggests that vitamin D represents a relevant metabolic biomarker. Low vitamin D is frequently found in PD. Similar findings were described efficaciously in previous studies [20, 27, 28]. However, at odds with other contributions [29, 30], we failed to detect correlations between vitamin D levels and PD symptom severity, as measured by both H&Y and UPDRS part III. In one of the larger studies conducted on PD patients, it was found a 18% of vitamin D deficiency and 47% of vitamin D insufficiency (compared to 7 and 40% in control, respectively). To note, they described a relation between “worse UPDRS scores” and specifically low 25(OH)D, as well as low total 25(OH)D levels (yet, the latter p = 0.02). However, similar to our findings, “associations with the HY scale failed to reach statistical significance” [20].

A limitation of our study relates to the evidence that only 5 PD patients exhibited MMSE < 20. Nevertheless, the presented cognitive performance are a reliable sample as it occurs in a natural, observational population of an unbiased clinical practice. If, on the other hand, we recruit a cohort characterised by a larger prevalence of a severe cognitive decline, chances for an opposite bias - the inclusion of PD dementia or dementia with Lewy bodies - would be higher.

Despite the fact that our PD cohort, as implied by the observational nature of the study, did not show a high prevalence of dementia, patients MMSE disclosed variable cognitive performance; this allowed to verify the possible correlation between serum 25(OH) D levels and cognitive scores; albeit in PD patients with mild cognitive impairment a tendency towards a lower vitamin D appeared, it did not reach significance.

Of course PD patients may suffer from a profound change of their daily activities (low exposure to sunlight, limited outdoor activities). Yet, since most of the control populations is represented by spouses, likely to share an analogous pattern of outdoor/indoor activities, the role of diurnal habits seems modest. Besides, also the notion that vitamin D levels failed to correlate with disease staging appears in apparent contradiction with the hypothesis claiming that severe motor impairment, as far as it collides with functional independence, imposes institutionalization and thus reduced sun exposure. The opportunity to extend the analysis of larger cohort is mandatory (especially if a larger cohort of patients will allow a comparison between de novo and advanced ones).

One of the striking result here presented regard the low vitamin D levels encountered in the population affected by motor neuron disease. Only few previous studies showed similar results [31,32]. In addition, vitamin D deficiency has been also documented in other neurodegenerative diseases, as recently documented in a study conducted by Terracciano et al., focusing myotonic dystrophy type 1 [22].

In this context, if the lack of vitamin D represents a general marker of senescence or a marker associated with neurodegeneration is not fully understood. There is strong evidence that vitamin D is involved in neuroprotection through various mechanisms: up-regulation of neurotrophic factors, antioxidative mechanisms, neuronal calcium regulation, nerve growth factor modulation [33-37], regulation of the toxicity of reactive oxygen species [38] and through immunomodulation and vasoprotection [7,10]. However, it is also possible that lower vitamin D levels could be a common factor in diseases that share neuro-inflammatory dysfunction as observed in MS. In accord with the association between MS and low vitamin D hematic concentration, observational studies suggest that adequate vitamin D nutrition affect the course of disease [39]; healthy whites with serum levels of 25(OH) D of 100 nmol/L or greater have a 50% reduced risk of developing MS as compared to those with levels below 75 nmol/L. Among MS patients, low 25(OH)D levels early in the disease course are a strong risk factor for long term MS MRI activity and clinical progression [23]. Noticably, MS has acquired recently the status of neurodegenerative disease.

**Conclusion**

Our study confirmed the evidence of a non-specific vitamin D deficiency in patients with PD, as well as in ALS patients, considered as a comparison cohort. Our study may support the hypothesis that PD predisposes to vitamin D deficiency (conceivably by limiting outdoor activities), whilst the role of vitamin D deficiency as active factor on disease progression is more than doubtful. The similar pattern of vitamin D concentration in ALS group (and the more dramatic deficiency in AD) is strongly evocative in that sense. In conclusion, although vitamin D supplementation has to be considered in different neurodegenerative conditions, at least in terms of metabolic rebalancing, its potential efficacy as a preventive strategy, in PD, is far from established.

**References**

Increased global visibility of articles through worldwide distribution and indexing

Sharing Option: Social Networking Enabled

Showcasing recent research output in a timely and updated manner

Quality and quick editorial, review and publication processing

Special issues on the current trends of scientific research

Authors, Reviewers and Editors rewarded with online Scientific Credits

OMICS International: Publication Benefits & Features

Unique features:
- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:
- 700 Open Access Journals
- 30,000 editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Embedded
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission/
